Tenderwize
Zurück zur Suche

Open house drug discount agreements

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline May 14, 2027 · 261 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge gem. § 130a (8c) SGB V ab 01.08.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

58/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

58 / 100

Komplexität

62 / 100

Risikofaktoren

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Duration until Jul 2027
  • Non-exclusive rebate agreements under Section 130a(8c) SGB V for oncology parenteral preparations made from finished medicinal products.
  • Active substances listed: bevacizumab (L01FG01), eribulin (L01XX41), rituximab (L01FA01), trastuzumab (L01FD01).
Vollständige Zusammenfassung anzeigen

Open-house pharmaceutical rebate agreement notice for three German regional lots (North Rhine-Westphalia, Hamburg, Schleswig-Holstein) covering oncology parenteral preparations made from finished medicinal products. The arrangement is non-exclusive, identical for all interested eligible pharmaceutical companies, with no award competition and no negotiated terms. Contract start is earliest 2025-08-01, duration up to 24 months, and the latest contract conclusion date is 2027-05-21. Submission is by email plus signed originals; electronic submission is otherwise marked not allowed in the notice metadata, so the submission mechanics should be checked carefully.

Risiken

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products and must remain so for the full contract term.
  • The company must have its registered seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Auftraggeber

Ort

Dortmund, DEU

Website

www.aok.de

Kennung

DE124159739

Tätigkeit

Health

Lose (3)

LOT-0001

North Rhine-Westphalia region

Regional open-house rebate agreement for North Rhine-Westphalia. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Jul 2025 - Jul 2027

Kategorie

Pharmaceutical products

Frist

Deadline May 14, 2027

LOT-0002

Hamburg region

Regional open-house rebate agreement for Hamburg. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Jul 2025 - Jul 2027

Kategorie

Pharmaceutical products

Frist

Deadline May 14, 2027

LOT-0003

Schleswig-Holstein region

Regional open-house rebate agreement for Schleswig-Holstein. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Jul 2025 - Jul 2027

Kategorie

Pharmaceutical products

Frist

Deadline May 14, 2027

Vergabedetails

Veröffentlichungsdatum
25 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
338688-2025

Dokumente (1)

Ähnliche Ausschreibungen